Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-02-17
2010-12-28
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C530S350000
Reexamination Certificate
active
07858324
ABSTRACT:
Urinary Cyr61 protein levels are up regulated in patients that have cancers of epithelial origin, i.e. breast cancer and ovarian cancer. Accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. Further, the amount of Cyr61 protein detected in a urine sample correlates with disease status such that Cyr61 levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of Cyr61 in urine provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient.
REFERENCES:
patent: 2004/0086504 (2004-05-01), Sampath et al.
patent: WO 01/98359 (2001-12-01), None
patent: WO 03/024308 (2003-03-01), None
Ohkaru et al, 1995, J Immunol method, 178: 99-111.
Muramatsu Y. et al. “Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury” Kidney International, New York, NY, US, vol. 62, No. 5, Nov. 1, 2002, pp. 1601-1610, XP002966736 ISSN: 0085-2538.
Pilarsky C.P. et al. “Expression of the Extracellular Matrix Signaling Molecule CYR61 Is Downregulated in Prostate Cancer” Prostate, Wiley-Liss, New York, NY, US, vol. 36, Jan. 1, 1998, pp. 85-91, XP002908329 Issn: 0270-4137.
Kunz M. et al. “Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells” Journal of Biological Chemistry, AL, vol. 278, No. 46, Nov. 14, 2003, pp. 45651-45660, xp003017167 ISSN: 0021-9258.
Mo et al. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol. Cell Biol. Dec. 2002, vol. 22, No. 24, pp. 8709-8720 see abstract.
Sugita et al., Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res. Jul. 15, 2002;62(14):3971-9.
Moses Marsha A.
Zhang Bo
Children's Medical Center Corporation
Davis Minh Tam
Yu Misook
LandOfFree
Cyr61 as a biomarker for diagnosis and prognosis of cancers... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyr61 as a biomarker for diagnosis and prognosis of cancers..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyr61 as a biomarker for diagnosis and prognosis of cancers... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4189962